2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1426

Inhibition Of Spermidine/Spermine N1-Acetyltransferase Activity – a New Therapeutical Concept In Rheumatoid Arthritis
Abstract Number: 762

Inhibition Of TGF-Beta Signaling In Articular Chondrocytes Leads To OA-Like Pathological Defects and Pain-Related Behavior Change In Mice
Abstract Number: 768

Inhibition Of X-Box Binding Protein 1 (XBP1) Is Chondroprotective By Promoting Autophagy and Inhibiting Catabolic Responses
Abstract Number: 552

Inhibitor Of Differentiation 3, A Transcription Factor Regulates Susceptibility To Kidney Disease
Abstract Number: 937

Inhibitor Of DNA Binding 1 Mediates Angiogenesis In Rheumatoid Arthritis By Recruitment Of Endothelial Progenitor Cells
Abstract Number: 1457

Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Abstract Number: 1265

Initial Benchmarking Of The Quality Of Medical Care Of Children and Adolescents With Lupus
Abstract Number: 1348

Initial Combination Therapy In Early Rheumatoid Arthritis: Which Patients Benefit?
Abstract Number: 2026

Initial Dose Of Prednisolone For Japanese Patients With Polymyalgia Rheumatica
Abstract Number: 1693

Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
Abstract Number: 1022

Initiation Of Biologic Therapy: The Patient Perspective
Abstract Number: 1168

Innate Immune Cell Production Of Interleukin-12 Drives CpG-Induced Macrophage Activation Syndrome
Abstract Number: 90

Insufficient Evidence For An Increase In Prevalence and Incidence Of Gout: A Systematic Review and Meta-Regression Analysis
Abstract Number: 391

Insulin Resistance As A Risk Factor For Subclinical Atherosclerosis In Rheumatoid Arthritis
Abstract Number: 1117

Integrated ¹⁸f-Fluoride Positron Emission Tomography and Magnetic Resonance Imaging Of The Spine – a Pilot Study and Comparison Of Signals In Patients With Axial Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].